Our in vitro and in vivo results suggest spatial inhibition of glycolytic metabolism and HIF-1α signaling may be a suitable approach for future arterial wall-based therapies that target disturbed flow-activated endothelium associated with focal atherosclerosis. This evidence concerns the gene HIF1A and atherosclerosis.